Churg-Strauss syndrome

Current Opinion in Rheumatology

Volumn 19, Issue 1, 2007, Pages 25-32

  Pagnoux, Christian ^a   Guilpain, Philippe ^a   Guillevin, Loïc ^a  

^a Institut Cochin   (France)

Author keywords

Antineutrophil cytoplasmic autoantibody; Asthma; Churg Strauss syndrome; Eosinophil; Vasculitis

Indexed keywords

ALLERGEN; ALPHA INTERFERON; AUTOANTIBODY; CORTICOSTEROID; CROMOGLYCATE DISODIUM; CYCLOPHOSPHAMIDE; EOSINOPHIL PEROXIDASE; FLUTICASONE; IMMUNOGLOBULIN; IMMUNOGLOBULIN E ANTIBODY; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 5 ANTIBODY; METHYLPREDNISOLONE; MYELOPEROXIDASE; NEUTROPHIL CYTOPLASMIC ANTIBODY; OMALIZUMAB; PREDNISONE; RITUXIMAB; SALMETEROL;

ASTHMA; CARDIOMYOPATHY; CARDIOTOXICITY; CELL INFILTRATION; CHURG STRAUSS SYNDROME; CLINICAL FEATURE; CLINICAL TRIAL; CYTOTOXICITY; DRUG MEGADOSE; GLOMERULONEPHRITIS; HISTOLOGY; HUMAN; HYPEREOSINOPHILIA; LOW DRUG DOSE; LUNG INFILTRATE; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SURVIVAL RATE; SURVIVAL TIME; SYMPTOM; VASCULAR DISEASE;

ADRENAL CORTEX HORMONES; ANTIBODIES, ANTINEUTROPHIL CYTOPLASMIC; CHURG-STRAUSS SYNDROME; CYCLOPHOSPHAMIDE; EOSINOPHILS; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; PHENOTYPE; RISK FACTORS;

EID: 33845362615     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/BOR.0b013e3280119854     Document Type: Review

References (90)

1. Churg J, Strauss L. Allergic angiitis and periarteritis nodosa. Am J Pathol 1951; 27:277-301.
2. Martin RM, Wilton LV, Mann RD. Prevalence of Churg-Strauss syndrome, vasculitis, eosinophilia and associated conditions: retrospective analysis of 58 prescription-event monitoring cohort studies. Pharmacoepidemiol Drug Saf 1999; 8:179-189.
3. Watts RA, Lane S, Scott DG. What is known about the epidemiology of the vasculitides? Best Pract Res Clin Rheumatol 2005; 19:191-207.
4. Mahr A, Guillevin L, Poissonnet M, Aymé S. Prevalences of polyarteritis nodosa, microscopic polyangiitis, Wegener's granulomatosis, and Churg-Strauss syndrome in a French urban multiethnic population in 2000: a capture-recapture estimate. Arthritis Rheum 2004; 51:92-99.
5. Haugeberg G, Bie R, Bendvold A, et al. Primary vasculitis in a Norwegian community hospital: a retrospective study. Clin Rheumatol 1998; 17:364-368.
6. Harrold LR, Andrade SE, Go AS, et al. Incidence of Churg-Strauss syndrome in asthma drug users: a population-based perspective. J Rheumatol 2005; 32:1076-1080. Annual incidence of Churg-Strauss syndrome among asthma patients was reported to be 64.4 per million patients by Martin et al. [2]. In this retrospective study conducted on 184 667 patients who had been prescribed ≥3 asthma drugs in three US centers between 1994 and 2000, 21 were classified as having 'probable/definite' Churg-Strauss syndrome. Therefore, overall annual incidence of Churg-Strauss syndrome among asthma patients, 34.6 per million patients, may be somewhat lower than previously reported, and with no significant variations in the studied population between 0 and 97 for sex, age group or period.
7. Loughlin JE, Cole JA, Rothman KJ, Johnson ES. Prevalence of serious eosinophilia and incidence of Churg-Strauss syndrome in a cohort of asthma patients. Ann Allergy Asthma Immunol 2002; 88:319-325.
8. Abu-Shakra M, Smythe H, Lewtas J, et al. Outcome of polyarteritis nodosa and Churg-Strauss syndrome. An analysis of twenty-five patients. Arthritis Rheum 1994; 37:1798-1803.
9. Lanham JG, Elkon KB, Pusey CD, Hughes GR. Systemic vasculitis with asthma and eosinophilia: a clinical approach to the Churg-Strauss syndrome. Medicine (Baltimore) 1984; 63:65-81.
10. Oh MJ, Lee JY, Kwon NH, Choi DC. Churg-Strauss syndrome: the clinical features and long-term follow-up of 17 patients. J Korean Med Sci 2006; 21:265-271.
11. Della Rossa A, Baldini C, Tavoni A, et al. Churg-Strauss syndrome: clinical and serological features of 19 patients from a single Italian centre. Rheumatology (Oxford) 2002; 41:1286-1294.
12. Haas C, Le Jeunne C, Choubrac P, et al. Churg-Strauss syndrome. Retrospective study of 20 cases [in French]. Bull Acad Natl Méd 2001; 185:1113-1130.
13. Gaskin G, Clutterbuck EJ, Pusey CD. Renal disease in the Churg-Strauss syndrome Diagnosis, management and outcome. Contrib Nephrol 1991; 94:58-65.
14. Reid AJ, Harrison BD, Watts RA, et al. Churg-Strauss syndrome in a district hospital. QJM 1998; 91:219-229.
15. Chumbley LC, Harrison EG Jr, DeRemee RA. Allergic granulomatosis and angiitis (Churg-Strauss syndrome). Report and analysis of 30 cases. Mayo Clin Proc 1977; 52:477-484.
16. Solans R, Bosch JA, Perez-Bocanegra C, et al. Churg-Strauss syndrome: outcome and long-term follow-up of 32 patients. Rheumatology (Oxford) 2001; 40:763-771.
17. Keogh KA, Specks U. Churg-Strauss syndrome: clinical presentation, antineutrophil cytoplasmic antibodies, and leukotriene receptor antagonists. Am J Med 2003; 115:284-290.
18. Sinico RA, Di Toma L, Maggiore U, et al. Prevalence and clinical significance of antineutrophil cytoplasmic antibodies in Churg-Strauss syndrome. Arthritis Rheum 2005; 52:2926-2935. In this Italian cohort of 93 patients with Churg-Strauss syndrome, 35 (37.6%) were ANCA-positive, yielding a perinuclear-labeling pattern for 74.3% of them, with MPO specificity for 92%. ANCA positivity was associated with higher frequencies of renal disease and alveolar capillaritis, but with lower rates of lung disease (other than alveolar hemorrhage) and cardiac involvement.
19. Guillevin L, Cohen P, Gayraud M, et al. Churg-Strauss syndrome. Clinical study and long-term follow-up of 96 patients. Medicine (Baltimore) 1999; 78:26-37.
20. Sablé-Fourtassou R, Cohen P, Mahr A, et al. Antineutrophil cytoplasmic antibodies and the Churg-Strauss syndrome. Ann Intern Med 2005; 143:632-638. This paper reports the results of the analysis of the 112 patients with Churg-Strauss syndrome enrolled in the trials conducted by the French Vasculitis Study Group between December 1995 and December 2002. ANCA were detected at diagnosis in 43 (38%) patients, who had more frequent renal involvement, peripheral neuropathy and biopsy-proven vasculitis, whereas ANCA-negative patients were more likely to have heart disease and fever. Results of the analyses support the notion that ANCA-positive and ANCA-negative patients with Churg-Strauss syndrome might differ phenotypically, with the former being more characteristic of a predominantly vasculitic pattern.
21. Hattori N, Ichimura M, Nagamatsu M, et al. Clinicopathological features of Churg-Strauss syndrome-associated neuropathy. Brain 1999; 122:427-439.
22. Hellemans S, Dens J, Knockaert D. Coronary involvement in the Churg-Strauss syndrome. Heart 1997; 77:576-578.
23. Petersen SE, Kardos A, Neubauer S. Subendocardial and papillary muscle involvement in a patient with Churg-Strauss syndrome, detected by contrast-enhanced cardiovascular magnetic resonance. Heart 2005; 91:e9.
24. Smedema JP, van Paassen P, van Kroonenburgh MJ, et al. Cardiac involvement of Churg-Strauss syndrome demonstrated by magnetic resonance imaging. Clin Exp Rheumatol 2004; 22:S75-S78.
25. Pela G, Tirabassi G, Pattoneri P, et al. Cardiac involvement in the Churg-Strauss syndrome. Am J Cardiol 2006; 97:1519-1524.
26. Davis MD, Daoud MS, McEvoy MT, Su WP. Cutaneous manifestations of Churg-Strauss syndrome: a clinicopathologic correlation. J Am Acad Dermatol 1997; 37:199-203.
27. Pagnoux C, Mahr A, Cohen P, Guillevin L. Presentation and outcome of gastrointestinal involvement in systemic necrotizing vasculitides: analysis of 62 patients with polyarteritis nodosa, microscopic polyangiitis, Wegener granulomatosis, Churg-Strauss syndrome, or rheumatoid arthritis-associated vasculitis. Medicine (Baltimore) 2005; 84:115-128.
28. Tsukadaira A, Okubo Y, Kitano K, et al. Eosinophil active cytokines and surface analysis of eosinophils in Churg-Strauss syndrome. Allergy Asthma Proc 1999; 20:39-44.
29. Umetsu DT, DeKruyff RH. Th1 and Th2 CD4+ cells in the pathogenesis of allergic diseases. Proc Soc Exp Biol Med 1997; 215:11-20.
30. Kiene M, Csernok E, Muller A, et al. Elevated interleukin-4 and interleukin-13 production by T cell lines from patients with Churg-Strauss syndrome. Arthritis Rheum 2001; 44:469-473.
31. ••], about the potential different clinical and physiopathogenic phenotypes that might exist in Churg-Strauss syndrome.
32. Manger BJ, Krapf FE, Gramatzki M, et al. IgE-containing circulating immune complexes in Churg-Strauss vasculitis. Scand J Immunol 1985; 21:369-373.
33. Hellmich B, Csernok E, Gross WL. Proinflammatory cytokines and autoimmunity in Churg-Strauss syndrome. Ann N Y Acad Sci 2005; 1051:121-131. A comprehensive review on the pathogenetic role of cytokines and ANCA in Churg-Strauss syndrome.
34. Mitsuyama H, Matsuyama W, Iwakawa J, et al. Increased serum vascular endothelial growth factor level in Churg-Strauss syndrome. Chest 2006; 129:407-411. Serum vascular endothelial growth factor levels were measured in 18 patients with Churg-Strauss syndrome, 19 patients with asthma and 12 patients with acute bronchitis. Levels were significantly higher in patients with Churg-Strauss syndrome and decreased after successful therapy. The sensitivity and specificity of distinguishing Churg-Strauss syndrome from asthma were 93.3% and 81.8%, respectively, suggesting that vascular endothelial growth factor might be associated with the pathogenesis of Churg-Strauss syndrome and could be a useful marker of the disease, and maybe a target for future therapy.
35. Falk RJ, Terrell RS, Charles LA, Jennette JC. Antineutrophil cytoplasmic autoantibodies induce neutrophils to degranulate and produce oxygen radicals in vitro. Proc Natl Acad Sci U S A 1990; 87:4115-4119.
36. Xiao H, Heeringa P, Hu P, et al. Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in mice. J Clin Invest 2002; 110:955-963.
37. Huugen D, Xiao H, van Esch A, et al. Aggravation of antimyeloperoxidase antibody-induced glomerulonephritis by bacterial lipopolysaccharide: role of tumor necrosis factor-alpha. Am J Pathol 2005; 167:47-58. The results of this study demonstrated the crucial in-vivo role of proinflammatory factors in the development of vasculitis in the animal models from Xiao et al. [36], who previously showed the direct pathogenic role of anti-MPO antibodies.
38. Heeringa P, Brouwer E, Tervaert JW, et al. Animal models of antineutrophil cytoplasmic antibody associated vasculitis. Kidney Int 1998; 53:253-263.
39. Guilpain P, Chanseaud Y, Tamby MC, et al. Pathogenesis of primary systemic vasculitides (I): ANCA-positive vasculitides [in French]. Presse Méd 2005; 34:1013-1022.
40. Guilpain P, Servettaz A, Tamby MC, et al. Pathogenesis of primary systemic vasculitides (II): ANCA-negative vasculitides [in French]. Presse Méd 2005; 34:1023-1033.
41. Termeer CC, Simon JC, Schopf E. Low-dose interferon alfa-2b for the treatment of Churg-Strauss syndrome with prominent skin involvement. Arch Dermatol 2001; 137:136-138.
42. Malm-Erjefalt M, Greiff L, Ankerst J, et al. Circulating eosinophils in asthma, allergic rhinitis, and atopic dermatitis lack morphological signs of degranulation. Clin Exp Allergy 2005; 35:1334-1340.
43. Peen E, Hahn P, Lauwers G, et al. Churg-Strauss syndrome: localization of eosinophil major basic protein in damaged tissues. Arthritis Rheum 2000; 43:1897-1900.
44. Tai PC, Holt ME, Denny P, et al. Deposition of eosinophil cationic protein in granulomas in allergic granulomatosis and vasculitis: the Churg-Strauss syndrome. Br Med J (Clin Res Ed) 1984; 289:400-402.
45. Cottin V, Tardy F, Gindre D, et al. Urinary eosinophil-derived neurotoxin in Churg-Strauss syndrome. J Allergy Clin Immunol 1995; 96:261-264.
46. Kurosawa M, Nakagami R, Morioka J, et al. Interleukins in Churg-Strauss syndrome. Allergy 2000; 55:785-787.
47. Schmitt WH, Csernok E, Kobayashi S, et al. Churg-Strauss syndrome: serum markers of lymphocyte activation and endothelial damage. Arthritis Rheum 1998; 41:445-452.
48. Schnabel A, Csernok E, Braun J, Gross WL. Inflammatory cells and cellular activation in the lower respiratory tract in Churg-Strauss syndrome. Thorax 1999; 54:771-778.
49. Higashi N, Mita H, Taniguchi M, et al. Urinary eicosanoid and tyrosine derivative concentrations in patients with vasculitides. J Allergy Clin Immunol 2004; 114:1353-1358.
50. Lane SE, Watts RA, Bentham G, et al. Are environmental factors important in primary systemic vasculitis? A case-control study. Arthritis Rheum 2003; 48:814-823.
51. Mathur S, Dooley J, Scheuer PJ. Quinine induced granulomatous hepatitis and vasculitis. Br Med J 1990; 300:613.
52. Imai H, Nakamoto Y, Hirokawa M, et al. Carbamazepine-induced granulomatous necrotizing angiitis with acute renal failure. Nephron 1989; 51:405-408.
53. Dietz A, Hubner C, Andrassy K. Macrolide antibiotic-induced vasculitis (Churg-Strauss syndrome) [in German]. Laryngorhinootologie 1998; 77:111-114.
54. Wechsler ME, Finn D, Gunawardena D, et al. Churg-Strauss syndrome in patients receiving montelukast as treatment for asthma. Chest 2000; 117:708-713.
55. Solans R, Bosch JA, Selva A, et al. Montelukast and Churg-Strauss syndrome. Thorax 2002; 57:183-185.
56. Pagnoux C, Guilpain P, Hauser T, Guillevin L. Churg-Strauss syndrome and leukotriene-modifying agents. Clin Pulm Med 2004; 11:349-354.
57. Wechsler M. Churg-Strauss syndrome with montelukast. Thorax 2001;56:417.
58. Wechsler ME, Garpestad E, Flier SR, et al. Pulmonary infiltrates, eosinophilia, and cardiomyopathy following corticosteroid withdrawal in patients with asthma receiving zafirlukast. JAMA 1998; 279:455-457.
59. Cooper SM, Libman BS, Lazarovich M. Churg-Strauss syndrome in a group of patients receiving fluticasone for asthma. J Rheumatol 2002; 29:2651-2652.
60. Lobel H, Machtey I, Eldror MY. Pulmonary infiltrates with eosinophilia in an asthmatic patient treated with disodium cromoglycate. Lancet 1972; 2: 1032.
61. Bili A, Condemi JJ, Bottone SM, Ryan CK. Seven cases of complete and incomplete forms of Churg-Strauss syndrome not related to leukotriene receptor antagonists. J Allergy Clin Immunol 1999; 104:1060-1065.
62. Guillevin L, Lhote F, Gayraud M, et al. Prognostic factors in polyarteritis nodosa and Churg-Strauss syndrome. A prospective study in 342 patients. Medicine (Baltimore) 1996; 75:17-28.
63. Gayraud M, Guillevin L, Cohen P, et al. Treatment of good-prognosis polyarteritis nodosa and Churg-Strauss syndrome: comparison of steroids and oral or pulse cyclophosphamide in 25 patients. French Cooperative Study Group for Vasculitides. Br J Rheumatol 1997; 36: 1290-1297.
64. Généreau T, Lortholary O, Leclerq P, et al. Treatment of systemic vasculitis with cyclophosphamide and steroids: daily oral low-dose cyclophosphamide administration after failure of a pulse intravenous high-dose regimen in four patients. Br J Rheumatol 1994; 33:959-962.
65. Pagnoux C, Cohen P, Mahr A, et al. Treatment of Churg-Strauss syndrome with poor prognosis factors. A prospective, randomized, multicenter trial comparing corticosteroids and 6 vs 12 cyclophosphamide pulses. Arthritis Rheum 2003; 49:S661.
66. Jayne DR, Rasmussen N, Andrassy K, et al. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med 2003; 349:36-44.
67. Jayne DR, Davies MJ, Fox CJ, et al. Treatment of systemic vasculitis with pooled intravenous immunoglobulin. Lancet 1991; 337:1137-1139.
68. Jayne DR, Lockwood CM. Pooled intravenous immunoglobulin in the management of systemic vasculitis. Adv Exp Med Biol 1993; 336: 469-472.
69. Danieli MG, Cappelli M, Malcangi G, et al. Long term effectiveness of intravenous immunoglobulin in Churg-Strauss syndrome. Ann Rheum Dis 2004; 63:1649-1654.
70. Guillevin L, Jarrousse B, Lok C, et al. Longterm followup after treatment of polyarteritis nodosa and Churg-Strauss angiitis with comparison of steroids, plasma exchange and cyclophosphamide to steroids and plasma exchange. A prospective randomized trial of 71 patients. The Cooperative Study Group for Polyarteritis Nodosa. J Rheumatol 1991; 18:567-574.
71. Jayne DR. How to induce remission in primary systemic vasculitis. Best Pract Res Clin Rheumatol 2005; 19:293-305. A comprehensive review of the latest recommendations for the treatment of primary systemic vasculitides.
72. Gaskin G. Plasma exchange of severe glomerulonephritis in ANCA-related vasculitides. A prospective study (MEPEX). World Apheresis Association Congress, Paris, France, 7-10 September 2002; Abstract number L83.
73. McDermott EM, Powell RJ. Cyclosporin in the treatment of Churg-Strauss syndrome. Ann Rheum Dis 1998; 57:258-259.
74. Keogh KA, Ytterberg SR, Fervenza FC, et al. Rituximab for refractory Wegener's granulomatosis: report of a prospective, open-label pilot trial. Am J Respir Crit Care Med 2006; 173:180-187.
75. Kaushik VV, Reddy HV, Bucknall RC. Successful use of rituximab in a patient with recalcitrant Churg-Strauss syndrome. Ann Rheum Dis 2006; 65:1116-1117.
76. Koukoulaki M, Smith KG, Jayne DR. Rituximab in Churg-Strauss syndrome. Ann Rheum Dis 2006; 65:557-559.
77. Levings MK, Sangregorio R, Galbiati F, et al. IFN-alpha and IL-10 induce the differentiation of human type 1 T regulatory cells. J Immunol 2001; 166:5530-5539.
78. Tatsis E, Schnabel A, Gross WL. Interferon-alpha treatment of four patients with the Churg-Strauss syndrome. Ann Intern Med 1998; 129:370-374.
79. Simon HU, Seelbach H, Ehmann R, Schmitz M. Clinical and immunological effects of low-dose IFN-alpha treatment in patients with corticosteroid- resistant asthma. Allergy 2003; 58:1250-1255.
80. Kips JC, O'Connor BJ, Langley SJ, et al. Effect of SCH55700, a humanized antihuman interleukin-5 antibody, in severe persistent asthma: a pilot study. Am J Respir Crit Care Med 2003; 167:1655-1659.
81. Zia-Amirhosseini P, Minthorn E, Benincosa LJ, et al. Pharmacokinetics and pharmacodynamics of SB-240563, a humanized monoclonal antibody directed to human interleukin-5, in monkeys. J Pharmacol Exp Ther 1999; 291: 1060-1067.
82. Klion AD, Law MA, Noel P, et al. Safety and efficacy of the monoclonal antiinterleukin-5 antibody SCH55700 in the treatment of patients with hypereosinophilic syndrome. Blood 2004; 103:2939-2941.
83. Flood-Page P, Menzies-Gow A, Phipps S, et al. Anti-IL-5 treatment reduces deposition of ECM proteins in the bronchial subepithelial basement membrane of mild atopic asthmatics. J Clin Invest 2003; 112:1029-1036.
84. Leckie MJ, ten Brinke A, Khan J, et al. Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet 2000; 356:2144-2148.
85. Ong YE, Menzies-Gow A, Barkans J, et al. Anti-IgE (omalizumab) inhibits latephase reactions and inflammatory cells after repeat skin allergen challenge. J Allergy Clin Immunol 2005; 116:558-564.
86. Busse WW. Antiimmunoglobulin E (omalizumab) therapy in allergic asthma. Am J Respir Crit Care Med 2001; 164:S12-S17.
87. D'Amato G. Role of anti-IgE monoclonal antibody (omalizumab) in the treatment of bronchial asthma and allergic respiratory diseases. Eur J Pharmacol 2006; 533:302-307.
88. Casale TB, Condemi J, LaForce C, et al. Effect of omalizumab on symptoms of seasonal allergic rhinitis: a randomized controlled trial. JAMA 2001; 286:2956-2967.
89. Leung DY, Sampson HA, Yunginger JW, et al. Effect of anti-IgE therapy in patients with peanut allergy. N Engl J Med 2003; 348:986-993.
90. Winchester DE, Jacob A, Murphy T. Omalizumab for asthma. N Engl J Med 2006; 355:1281-1282.